Human Genome Sciences Reports First Phase II Findings For TRAIL Receptor Agonist Mapatumumab
This article was originally published in The Pink Sheet Daily
Phase II results termed “unimpressive,” though firm says potential partners show interest.
You may also be interested in...
Maryland biotech swaps oncology candidates for reduced royalties on type 2 diabetes candidate.
Solvay may need a more restrictive Risk Evaluation and Mitigation Strategy for AndroGel 1% to adequately warn against the danger of secondary transfer of the testosterone gel, according to some members of FDA's Pediatric Advisory Committee
Agency comes to same conclusion as advisory committee: the risky schizophrenia drug could get approved if an appropriate patient group is identified.